PF 00217830

a D2 receptor partial agonist for treating schizophrenia and bipolar disorder; structure in first source

Also Known As:

3,4-dihydro-7-(4-(1-naphthalenyl)-1-piperazinyl)butoxy-1,8-naphthyridin-2(1H)-one; PF-00217830; PF-217830; PF00217830

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Akunne, Hyacinth C: 1 article (05/2011)
2.	Choi, Chung: 1 article (05/2011)
3.	Favor, David A: 1 article (05/2011)
4.	Fay, Lorraine K: 1 article (05/2011)
5.	Fitzgerald, Lawrence: 1 article (05/2011)
6.	Johnson, Douglas S: 1 article (05/2011)
7.	Nicholls, Kim: 1 article (05/2011)
8.	Repine, Joseph T: 1 article (05/2011)
9.	Serpa, Kevin A: 1 article (05/2011)
10.	Snyder, Bradley J: 1 article (05/2011)

1.	Schizophrenia (Dementia Praecox) 05/01/2011 - "Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder."
2.	Catalepsy 05/01/2011 - "This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED=0.3mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg)."
3.	Bipolar Disorder (Manic Depressive Psychosis) 05/01/2011 - "Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder."

1.	Piperazine